2023 Was a troublesome 12 months for that biopharma field, with quite a few companies downsizing and restructuring their workforces to stay afloat. You will discover signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifetime sciences field during the latter Element of 2023 and also https://sites.google.com/view/bio-sites/blog